Ras (Kras or Nras) Gene Mutation clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for

  • IK-595 in RAS- or RAF-altered Advanced Tumors

    open to eligible people ages 18 years and up

    This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.

    Orange, California and other locations

Our lead scientists for Ras (Kras or Nras) Gene Mutation research studies include .

Last updated: